5.585

5.78% 0.305

Pre-market: 5.63 0.045 +0.81%

Compass Therapeutics Inc (CMPX)

Overview News Price History Financials Discussions Forecast

Compass Therapeutics Inc stock is traded at $5.585, with a volume of 1.05M. It is up +5.78% in the last 24 hours and up +47.36% over the past month. Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Previous Close:

$5.28

Open:

$5.25

24h Volume:

1.05M

Relative Volume:

0.56

Market Cap:

$993.36M

Revenue:

Net Income/Loss:

$-45.44M

P/E Ratio:

-15.96

EPS:

-0.35

Net Cash Flow:

$-42.28M

1W Performance:

+3.62%

1M Performance:

+47.36%

6M Performance:

+157.37%

1Y Performance:

+269.87%

1-Day Range:

$5.25

$5.605

1-Week Range:

$5.13

$5.86

52-Week Range:

$1.33

$5.86

Compass Therapeutics Inc Stock (CMPX) Company Profile

Name

Compass Therapeutics Inc

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

617-500-8099

Address

80 GUEST STREET, BOSTON

Employee

Twitter

Next Earnings Date

2025-08-08

Latest SEC Filings

CMPX's Discussions on Twitter

Compare CMPX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CMPX Compass Therapeutics Inc	5.585	939.11M	0	-45.44M	-42.28M	-0.35
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-25	Initiated	Canaccord Genuity	Buy
Dec-03-25	Initiated	Cantor Fitzgerald	Overweight
Dec-03-25	Initiated	Citizens JMP	Mkt Outperform
Jul-01-25	Resumed	Raymond James	Outperform
Apr-02-25	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-24-25	Initiated	Guggenheim	Buy
Feb-19-25	Initiated	Piper Sandler	Overweight
Dec-23-24	Initiated	D. Boral Capital	Buy
Nov-15-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jan-31-23	Initiated	Jefferies	Buy
Jan-27-23	Initiated	Stifel	Buy
May-23-22	Resumed	H.C. Wainwright	Buy
Mar-15-22	Initiated	Ladenburg Thalmann	Buy
Jan-19-22	Initiated	B. Riley Securities	Buy
Dec-22-21	Initiated	Raymond James	Outperform
Dec-20-21	Initiated	SVB Leerink	Outperform
Dec-15-21	Initiated	Wedbush	Outperform

View All

Compass Therapeutics Inc Stock (CMPX) Latest News

Dec 04, 2025

Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at Citizens Jmp - MarketBeat

Dec 04, 2025

Compass Therapeutics (NASDAQ:CMPX) Now Covered by Analysts at Canaccord Genuity Group - MarketBeat

Dec 04, 2025

Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Citizens Jmp - Defense World

Dec 04, 2025

Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World

Dec 04, 2025

Dec 03, 2025

Citizens Initiates Coverage of Compass Therapeutics (CMPX) with Market Outperform Recommendation - Nasdaq

Dec 03, 2025

Compass Therapeutics (NASDAQ:CMPX) Trading Down 6%Time to Sell? - MarketBeat

Dec 03, 2025

CMPX Analyst Rating Update: Citizens Initiates Coverage with Market Outperform | CMPX Stock News - GuruFocus

Dec 03, 2025

This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Dec 03, 2025

Cantor Fitzgerald Initiates Compass Therapeutics at Overweight - marketscreener.com

Dec 03, 2025

Cantor Fitzgerald initiates Compass Therapeutics stock with Overweight rating By Investing.com - Investing.com UK

Dec 03, 2025

Compass Therapeutics stock initiated at Market Outperform by Citizens - Investing.com Canada

Dec 03, 2025

Dec 02, 2025

The growth track for Compass Therapeutics Inc (CMPX) has changed recently - Setenews

Dec 02, 2025

Compass Therapeutics (NASDAQ:CMPX) Sets New 52-Week HighTime to Buy? - MarketBeat

Dec 02, 2025

Dec 01, 2025

Compass Therapeutics stock hits 52-week high at 5.86 USD By Investing.com - Investing.com Nigeria

Dec 01, 2025

Compass Therapeutics (CMPX) Is Up 17.2% After Analyst Highlights Pipeline Progress and Anticipated Tovecimig Data – Has the Bull Case Changed? - Yahoo Finance

Dec 01, 2025

Analysts Issue Forecasts for CMPX FY2025 Earnings - Defense World

Dec 01, 2025

Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement - Yahoo Finance

Dec 01, 2025

Nov 30, 2025

A Look at Compass Therapeutics (CMPX) Valuation Following Strong CTX-10726 Preclinical Data and Management Update - Yahoo Finance

Nov 30, 2025

Compass Therapeutics (CMPX): Evaluating Valuation After a 55% 1-Month Share Price Surge - sahmcapital.com

Nov 30, 2025

Nov 29, 2025

Compass Therapeutics (NASDAQ:CMPX) Trading Up 8.1%Time to Buy? - MarketBeat

Nov 29, 2025

Nov 28, 2025

What analysts say about Compass Therapeutics Inc stockMACD Trading Signals & Free Daily Stock Hotspot Analysis - earlytimes.in

Nov 28, 2025